Evidence map›Paper›PMID 41578116›Full record

ReviewAsia-Pacific journal of clinical oncology2026

Managing Skin Side Effects Associated With Oncology Treatments: Asian Perspective on Use of Dermocosmetics.

Meng Pan, Jianguo Sun, Makoto Kawashima, You Chan Kim, Mison Chun, Chia-Yu Chu, Yi-Hsin Liang, Mee Chang, Delphine Kerob, Brigitte Dreno

Abstract readReview
In one paragraph

Review in Asia-Pacific journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Meng PanDepartment of Dermatology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Jianguo SunCancer Institute, Xianqiao Hospital, Army Military Medical University, Chongqing, China.
Makoto KawashimaTokyo Women's Medical University, Tokyo, Japan.
You Chan KimDepartment of Dermatology, Ajou University School of Medicine, Suwon, South Korea.
Mison ChunAjou University School of Medicine, Suwon, South Korea.
Chia-Yu ChuDepartment of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Yi-Hsin LiangNational Taiwan University Hospital, Taipei, Taiwan.
Mee ChangDepartment of Medicine & Therapeutics, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
Delphine KerobLa Roche-Posay Laboratoire Dermatologique, Paris, France.
Brigitte DrenoNantes University, Nantes, France.

Funding

Cosmetics Active International
6 · The paper itself

Abstract

Skin adverse events (AEs) frequently accompany all types of anticancer treatments. The type and course of these skin AEs with different cancer treatments have been described and may be considered to generally have a similar pattern in differing world regions. However, some populations, including Asian populations, may have presentations that vary somewhat based on skin sensitivity and other factors. Education of both healthcare professionals and patients about how to identify, prevent, and manage these skin AEs is imperative in this era when not only is cancer on the rise but also there are longer life expectancies due to new, improved treatment approaches. Maintaining a good quality of life is a key target in oncology management, and skin AEs can have a profound effect on patient comfort, patient self-image, and psychological ability to cope. Today, proactive skincare regimens, including dermocosmetics, can be put in place to minimize potential for AEs. If skin AEs occur, dermocosmetics may be employed alone or to augment the effects of medical treatments. Optimally, cancer patients should be managed by a multidisciplinary team with knowledge of skin and treatment-related AEs. This publication discusses how recent international guidance on best-practices use of dermocosmetics can be adapted to the North Asia region (China, Hong Kong, Japan, Republic of Korea, and Taiwan).

Indexed as

Antineoplastic AgentsNeoplasmsSkin DiseasesAsiaHumansAntineoplastic Agentscancer treatmentcosmeceuticalsdermocosmeticsoncologyskin toxicities

Identifiers

PMID41578116
PMCPMC13007751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.